PURPOSE: A combination of mitoxantrone plus prednisone is preferable to prednisone
alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer. The …

PURPOSE This phase II study was designed to assess the effects of mitoxantrone with
prednisone in patients with metastatic prostate cancer who had progressed on hormonal …

PURPOSE To investigate the benefit of chemotherapy in patients with symptomatic hormone-
resistant prostate cancer using relevant end points of palliation in a randomized controlled …

Purpose Palliation of bone pain can be achieved in men with androgen-independent
prostate cancer treated with docetaxel and estramustine (DE) or mitoxantrone and …

Purpose: The TAX-327 study randomized 1,006 men with metastatic hormone-refractory
prostate cancer to receive 3-weekly docetaxel, weekly docetaxel, or mitoxantrone, each with …

Purpose: To compare the incidence of palliative response in patients with hormone-resistant
prostate cancer (HRPC) treated with mitoxantrone and prednisone (MP) plus clodronate with …

PURPOSE We previously reported that enzalutamide improved overall survival when added
to standard of care in metastatic, hormone-sensitive prostate cancer. Here, we report its …

Abstract Background and Methods. The quality of life in patients who elected to receive
hormonal therapy for newly diagnosed asymptomatic metastatic prostate cancer was …

Background Mitoxantrone plus prednisone reduces pain and improves the quality of life in
men with advanced, hormone-refractory prostate cancer, but it does not improve survival …

Purpose Chemohormonal therapy with docetaxel and androgen deprivation therapy (ADT+
D) for metastatic hormone-sensitive prostate cancer improves overall survival as compared …